Company Profile
Cellectis Stock Price, News & Analysis
Company overview
Business overview
Cellectis is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Cellectis is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Cellectis follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Cellectis sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
CLLS is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Cellectis has a much cleaner development path now that lasme-cel is in pivotal Phase 2 and the BLA timeline is on the table. The interim data, the full Phase 1 results for eti-cel, and the 2028 filing path all give the company a more concrete off-the-shelf CAR-T story than it had before.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.